has broadly authorized Johnson & Johnson to distribute doses made by Emergent on an emergency basis. The agency has cleared the equivalent of up to 75 million doses, but tens of millions remain in limbo. In a conference call with investors on Thursday, Emergent executives announced a $41.5 million hit from being forced to discard doses the F.D.A. had deemed unusable, and said the company had spent another $12.4 million to address manufacturing issues in Baltimore. Out of public view, however, concern about the company’s ability to deliver was mounting, as The Times has reported.

Source: New York Times July 30, 2021 21:45 UTC